BioCentury
ARTICLE | Clinical News

Myriad starts Phase II Alzheimer's trial

June 25, 2003 7:00 AM UTC

MYGN started a U.K. and Canadian Phase II trial of its MPC-7869 R-flurbiprofen to treat mild-to-moderate Alzheimer's disease (AD). The double-blind, placebo-controlled 12-month trial will enroll about...